Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Conference call and webcast to begin at 8:30 AM ET
电话会议和网络直播将于东部时间上午8:30开始
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.
德克萨斯州奥斯汀，2024年10月31日(全球新闻社)——cassava sciences公司(纳斯达克: SAVA)，一家专注于阿尔茨海默病的临床阶段生物技术公司，今天宣布将于11月7日星期四上午8:30举行电话会议。
| Event details: | |
| Date: | Thursday, November 7th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | |
| Or | |
| Audio Webcast: | |
| 事件详情： | |
| 日期： | 11月7日星期四 |
| 时间： | 美国东部时间上午8:30 |
| 音频网络广播： | |
| 或者 | |
| 音频网络广播： | |
A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast.
音频网络广播的重播也将在cassava sciences网站的"公司演示"页面上提供，持续90天。
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease.
关于Cassava Sciences，Inc.
cassava sciences是一家总部位于得克萨斯州奥斯汀的处于临床阶段的生物技术公司。我们的使命是检测和治疗神经退行性疾病，比如阿尔茨海默氏病。
Simufilam is Cassava Sciences' small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
Simufilam是cassava sciences的口服小分子药物候选，目前正在进行用于治疗阿尔茨海默氏病的三期临床试验。Simufilam瞄准filamin A上的特定位点，这是大脑中某些受体相互作用至关重要的支架蛋白。cassava sciences相信，simufilam打断了β淀粉样蛋白42与脑部受体的结合，并可能影响阿尔茨海默氏病的发展过程。cassava sciences拥有其产品候选和相关技术的独家全球使用权，无需向任何第三方支付版税。
For more information, please visit:
欲了解更多信息，请访问：
For More Information Contact:
欲知详情，请联系：
Investors
Sandya van der Weid
svonderweid@lifesciadvisors.com
投资者
Sandya van der Weid
svonderweid@lifesciadvisors.com
Media
Sitrick And Company
Mike_Sitrick@Sitrick.com
媒体
Sitrick And Company
Mike_Sitrick@Sitrick.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
公司
Eric Schoen, 首席财务官
(512) 501-2450
ESchoen@CassavaSciences.com
